Department of Endocrinology and Metabolic Diseases, IRCCS Auxologico Italian Institute, Milan, Italy -
Department of Endocrinology and Metabolic Diseases, IRCCS Auxologico Italian Institute, Milan, Italy.
Minerva Endocrinol. 2020 Dec;45(4):354-375. doi: 10.23736/S0391-1977.20.03228-9. Epub 2020 Jul 23.
Differential diagnosis between constitutional delay of growth and puberty (CDGP), partial growth hormone deficiency (pGHD) and congenital hypogonadotropic hypogonadism (cHH) may be difficult. All these conditions usually present with poor growth in pre- or peri-pubertal age and they may recur within one familial setting, constituting a highly variable, but somehow common, spectrum of pubertal delay.
Narrative review of the most relevant English papers published between 1981 and march 2020 using the following search terms "constitutional delay of growth and puberty," "central hypogonadism," "priming," "growth hormone deficiency," "pituitary," "pituitary magnetic resonance imaging," with a special regard to the latest scientific acquisitions.
CDGP is by far the most prevalent entity in boys and recurs within families. pGHD is a rare, often idiopathic and transient condition, where hypostaturism presents more severely. Specificity of pGHD diagnosis is increased by priming children before growth hormone stimulation test (GHST); pituitary MRI and genetic analysis are recommended to personalize future follow-up. Diagnosing cHH may be obvious when anosmia and eunuchoid proportions concomitate. However, cHH can either overlap with pGHD in forms of multiple pituitary hormone deficiencies (MPHD) or syndromic conditions either with CDGP in family pedigrees, so endocrine workup and genetic investigations are necessary. The use of growth charts, bone age, predictors of adult height, primed GHST and low dose sex steroids (LDSS) treatment are recommended.
Only a step-by-step diagnostic process based on appropriate endocrine and genetic markers together with LDSS treatment can help achieving the correct diagnosis and optimizing outcomes.
生长和青春期 constitutional delay(CDGP)、部分生长激素缺乏症(pGHD)和先天性低促性腺激素性性腺功能减退症(cHH)之间的鉴别诊断可能较为困难。所有这些情况通常在青春期前或青春期时表现为生长不良,并且可能在一个家族中反复发作,构成了一个高度可变但在某种程度上常见的青春期延迟谱。
使用以下搜索词对 1981 年至 2020 年 3 月期间发表的最相关的英文文献进行了叙述性综述,包括“constitutional delay of growth and puberty”、“central hypogonadism”、“priming”、“growth hormone deficiency”、“pituitary”、“pituitary magnetic resonance imaging”,特别关注最新的科学研究成果。
到目前为止,CDGP 是男孩中最常见的实体,并且在家族中反复发作。pGHD 是一种罕见的、通常是特发性和短暂的疾病,身材矮小更为严重。在生长激素刺激试验(GHST)前对儿童进行预刺激可提高 pGHD 诊断的特异性;建议进行垂体 MRI 和基因分析以个性化未来的随访。当嗅觉丧失和男性体型比例同时存在时,cHH 的诊断可能很明显。然而,cHH 可能与 pGHD 在多种垂体激素缺乏症(MPHD)或综合征的形式中重叠,也可能与家族系谱中的 CDGP 重叠,因此需要进行内分泌检查和基因研究。建议使用生长图表、骨龄、成人身高预测因子、预刺激 GHST 和低剂量性激素(LDSS)治疗。
只有基于适当的内分泌和遗传标志物以及 LDSS 治疗的逐步诊断过程,才能帮助做出正确的诊断并优化结果。